Seer

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seer reports strong Q4 earnings, eyes revenue growth in 2023

Seer's Q4 2022 earnings reflect robust growth, driven by product sales and service projects. While challenges persist in China market access, the company is poised for revenue growth in 2023 through consumables and service contracts.

Seer (SEER) reports strong Q1 revenue growth and technology validation

Seer's Q1 performance showed revenue growth and a focus on disciplined expense management for financial strength.
The company's emphasis on Proteograph technology and customer validation positions it well for future growth.
While facing challenges in sales cycles and market opportunities, Seer is leveraging strategic initiatives for growth.

Seer reports revenue growth amidst challenges, focuses on strategic initiatives

Seer's Q2 performance showed revenue growth but faced a net loss due to operating expenses, prompting strategic cost management and sales cycle improvements.
Strengths lie in product expansion, strategic collaborations, and a focus on consumable margins, positioning Seer well in the proteomics market.
Challenges in adoption and cost alignment require focused efforts, while opportunities in customer engagement and strategic programs offer growth potential.

Seer reports Q3 revenue growth amidst macro challenges and partnerships

Seer's Q3 performance showed revenue growth but with a net loss, ending the quarter with a strong cash position. The company faces challenges from macroeconomic uncertainty impacting revenue and sales cycles. Seer's initiatives and partnerships present opportunities for growth and market adoption.

Seer reports revenue growth in 2023, eyes innovation for 2024

Seer's 2023 performance showed revenue growth and cost management improvements, ending the year well-funded.
Strong demand for technology and programs, coupled with a focus on innovation and evidence, positions Seer for growth.
Challenges in China and Europe markets require strategic navigation, while opportunities lie in revenue growth and technology advancements.

Seer reports Q1 revenue of $3.1M, focuses on innovation and cost-saving

Seer's Q1 2024 performance reflected revenue of $3.1 million, with cost-saving measures leading to reduced operating expenses. The company faces challenges in revenue growth due to slow platform adoption but is leveraging strengths in innovative technology and research support programs. Strategic initiatives like market share repurchase and global expansion present opportunities for future growth.

Seer reports revenue growth and strategic partnerships amid profitability challenges

Seer's Q3 performance reflects revenue growth and strategic collaborations despite financial losses.
The company's strong cash reserves and partnerships signal resilience and potential for market expansion.
While facing profitability challenges, Seer's innovative technology and market demand offer growth opportunities.
Navigating market uncertainties and optimizing financial performance are key focus areas for Seer.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seasoned life sciences executive adds extensive global sales expertise to drive commercial efforts Seasoned life sciences executive adds extensive global sales expertise to drive commercial efforts

Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite™ for deep, unbiased, precise, scalable proteomics. The paper, entitled “Engineered Nanoparticles Enable Deep Proteomics Studies at Scale by Leveraging Tunable Nano-Bio Interactions,” was published in The Proceedings of the National Academy of Sciences (PNAS) by an interdisciplinary team of scientists from Seer, Oregon Health Sciences University, Massachusetts Institute of Technology, and Harvard Medical School. The study examines in detail the relationship between the unique physicochemical properties of a panel of proprietary engineered nanoparticles (NPs) and the diverse pattern of protein sampling that is enabled by a unique nano-bio interface that is created between a given NP surface and a given biological sample. The Seer machine learning model developed in this paper enhances understanding of the molecular interactions that occur at the nano-bio interface and shows how future NPs may be rationally designed using machine learning to differentially interrogate specific protein families.

Seer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbiased, Precise, Scalable Proteomics in the Proceedings of the National Academy of Sciences

Seer, Inc. (SEER) CEO Omid Farokhzad on Q4 2021 Results - Earnings Call Transcript

Demonstrated tangible market progress and shipped 17 instruments through year end 2021 Demonstrated tangible market progress and shipped 17 instruments through year end 2021

Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating virtually in the upcoming Cowen 42nd Annual Health Care Conference.

Seer to Present at the Cowen 42nd Annual Health Care Conference

Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seer, Inc. (SEER) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2021

Company has already booked multiple orders and established COEs in three major geographies Company has already booked multiple orders and established COEs in three major geographies

Updated: Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program

Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies

Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies

Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Seer securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Seer, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation - SEER

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seer is the subject of a research report published by the Bear...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Investors with Losses to Contact the Firm

REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada.

Seer Appoints Meeta Gulyani to its Board of Directors

Los Angeles, California--(Newsfile Corp. - November 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seer is the subject of a research report published by the Bear...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seer is the subject of a research report published by the Bear...

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Seer, Inc. and Encourages Investors With Losses to Contact the Firm

REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available on the conference website beginning on November 22, 2021. A link to the presentation will also be available on the Investors section of the company's website at investors.seer.bio.

Seer to Participate in the Piper Sandler Virtual Healthcare Conference

Los Angeles, California--(Newsfile Corp. - November 10, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seer is the subject of a research report published by the Bear...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Investors with Losses to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - November 10, 2021) - Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/seer.What is this all about?On November 4, 2021, The Bear Cave, a newsletter authored by Edwin Dorsey, issued a short report alleging that Seer appears to...

SEER INVESTIGATION: Block & Leviton Is Investigating Seer Inc. for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged To Contact the Firm

Seer, Inc. (SEER) CEO Omid Farokhzad on Q3 2021 Results - Earnings Call Transcript

Customers demonstrate novel methods using the Proteograph Product Suite and continued commercial momentum ahead of Broad Release in early 2022 Customers demonstrate novel methods using the Proteograph Product Suite and continued commercial momentum ahead of Broad Release in early 2022

Seer Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Rachel Haurwitz, Ph.D. to serve on its Board of Directors, effective November 8, 2021. Dr. Haurwitz is currently CEO of Caribou Biosciences, Inc. a clinical-stage biopharmaceutical company developing genome-edited off-the-shelf immune cell therapies for the treatment of cancer. Concurrent with this appointment, David Singer will step down from the Board of Directors.

Seer Appoints Rachel Haurwitz, Ph.D., to its Board of Directors

Los Angeles, California--(Newsfile Corp. - November 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seer is the subject of a research report published by the Bear...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $SEER #SEER--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Investors with Losses to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - November 5, 2021) - Holzer & Holzer, LLC is investigating whether Seer, Inc. ("Seer" or the "Company") (NASDAQ: SEER) complied with federal securities laws. On November 4, 2021, Seeking Alpha published a report entitled "Seer Inc. falls after new short call from The Bear Cave." According to Seeking Alpha, The Bear Cave short report alleged Seer misled investors about its recent Chinese distribution partnership, customer base, and management's track record. On...

News for Seer Stock (SEER)